Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation?

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2219-2221

  Savani, Bipin N ^a   Goodman, Stacey ^a   Johnbarrett, A ^b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIBODY; WART VIRUS VACCINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG EFFICACY; FEMALE GENITAL TRACT CANCER; HEAD AND NECK CARCINOMA; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MOUTH CARCINOMA; NONHUMAN; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RECIPIENT; REVIEW; SECOND CANCER; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; VIRUS REACTIVATION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; FEMALE; GENITAL NEOPLASMS, FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; NEOPLASMS, SECOND PRIMARY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 65249086792     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3099     Document Type: Review

References (28)

1. Socie G, Stone JV,Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341:14-21. PubMed doi:10.1056/NEJM199907013410103.
2. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007;110:3784-92. PubMed doi:10.1182/blood-2007-03-082933.
3. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999;131:738-44. PubMed.
4. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009;113:1175-83. Epub 2008 Oct 29.
5. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001;19: 464-71. PubMed.
6. Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13:1121-34. PubMed doi:10.1016/j.bbmt.2007.07.002.
7. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336:897-904. PubMed doi:10.1056/ NEJM199703273361301.
8. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000;18: 348-57. PubMed.
9. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005;105:3802-11. PubMed doi:10.1182/blood-2004-09-3411.
10. Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006;24:1119-26. PubMed doi:10.1200/JCO.2005.02.7052.
11. Savani BN, Stratton P, Shenoy A, et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation- implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008;14:1072-5. PubMed doi:10.1016/j.bbmt.2008.07.005.
12. Ozsaran AA, Ates T, Dikmen Y, et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999;20:127-30. PubMed.
13. Ulrich C, Hackethal M, Meyer T, et al. Skin infections in organ transplant recipients. J Dtsch Dermatol Ges 2008;6:98-105. PubMed doi: 10.1111/j.1610-0387.2007.06431.x.
14. Stockfleth E, Nindl I, Sterry W, et al. Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg 2004;30:604-9. PubMed doi:10.1111/j.1524-4725.2004.00144.x.
15. Stockfleth E, Ulrich C, Meyer T, Arndt R, Christophers E. Skin diseases following organ transplantation-risk factors and new therapeutic approaches. Transplant Proc 2001;33:1848-53. PubMed doi:10.1016/S0041-1345(00)02743-3.
16. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-9. PubMed doi:10.1001/jama.297. 8.813.
17. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. SexTransm Dis 2006;33:502-8. PubMed doi:10.1097/01.olq.0000204545.89516.0a.
18. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423- 8. PubMed doi:10.1056/NEJM199802123380703.
19. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26. PubMed doi:10.1093/aje/kwf180.
20. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 2004;189:46-50. PubMed doi:10.1086/380466.
21. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23. PubMed doi:10.1086/315086.
22. Rose B, Wilkins D, Li W, et al. Human papillomavirus in the oral cavity of patients with and without renal transplantation. Transplantation 2006;82:570-3. PubMed doi:10.1097/01.tp.0000231706.79165.e5.
23. Onozawa M, Hashino S, Darmanin S, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008;14:1226-30. PubMed doi:10.1016/j.bbmt.2008.08.007.
24. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75. PubMed doi:10.1158/1055-9965. EPI-04-0551.
25. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56. PubMed doi:10.1056/NEJMoa065497.
26. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73. PubMed doi:10.1038/sj.bjc.6600688.
27. Jensen P, Moller B, Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000;42:307. PubMed doi:10.1016/S0190-9622(00)90154-3.
28. Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997;349:398. PubMed doi:10.1016/S0140- 6736(97)80015-3.